Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.

Abstract

The treatment of multi-drug resistant (MDR) cancer is a clinical challenge. Many MDR cells over-express epidermal growth factor receptor (EGFR). We exploit this expression through the development of EGFR-targeted, polymer blend nanocarriers for the treatment of MDR cancer using paclitaxel (a common chemotherapeutic agent) and lonidamine (an experimental drug; mitochondrial hexokinase 2 inhibitor). An orthotopic model of MDR human breast cancer was developed in nude mice and used to evaluate the safety and efficacy of nanoparticle treatment. The efficacy parameters included tumor volume measurements from day 0 through 28 days post-treatment, terminal tumor weight measurements, tumor density and morphology assessment through hematoxylin and eosin staining of excised tumors, and immunohistochemistry of tumor sections for MDR protein markers (P-glycoprotein, Hypoxia Inducible Factor, EGFR, Hexokinase 2, and Stem Cell Factor). Toxicity was assessed by tracking changes in animal body weight from day 0 through 28 days post-treatment, by measuring plasma levels of the liver enzymes ALT (Alanine Aminotransferase) and LDH (lactate dehydrogenase), and by white blood cell and platelet counts. In these studies, this nanocarrier system demonstrated superior efficacy relative to combination (paclitaxel/lonidamine) drug solution and single agent treatments in nanoparticle and solution form. The combination nanoparticles were the only treatment group that decreased tumor volume, sustaining this decrease until the 28 day time point. In addition, treatment with the EGFR-targeted lonidamine/paclitaxel nanoparticles decreased tumor density and altered the MDR phenotype of the tumor xenografts. These EGFR-targeted combination nanoparticles were considerably less toxic than solution treatments. Due to the flexible design and simple conjugation chemistry, this nanocarrier system could be used as a platform for the development of other MDR cancer therapies; the use of this system for EGFR-targeted, combination paclitaxel/lonidamine therapy is an advance in personalized medicine.

• Authors: Lara Milane, Zhenfeng Duan, Mansoor Amiji
• Journal: PloS one (PLoS One) Vol. 6 Issue 9 Pg. e24075 ( 2011) ISSN: 1932-6203 [Electronic] United States
• PMID: 21931642 (Publication Type: Journal Article, Research Support, American Recovery and Reinvestment Act, Research Support, N.I.H., Extramural)

Chemical References

• ATP Binding Cassette Transporter, Subfamily B
• Hypoxia-Inducible Factor 1, alpha Subunit
• Indazoles
• ErbB Receptors
• Paclitaxel
• lonidamine

Topics

• ATP Binding Cassette Transporter, Subfamily B (metabolism)
• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cell Line, Tumor
• Drug Delivery Systems
• Drug Resistance, Multiple (drug effects)
• Drug Resistance, Neoplasm (drug effects)
• ErbB Receptors (antagonists & inhibitors, metabolism)
• Female
• Humans
• Hypoxia-Inducible Factor 1, alpha Subunit (metabolism)
• Immunohistochemistry
• Indazoles (administration & dosage)
• Mice
• Mice, Nude
• Microscopy, Electron, Scanning
• Nanoparticles (administration & dosage, ultrastructure)
• Neoplasms (drug therapy, metabolism, pathology)
• Paclitaxel (administration & dosage)
• Treatment Outcome
• Tumor Burden (drug effects)
• Xenograft Model Antitumor Assays